- Home
- GGZ vs BDTX Comparison
GGZ vs BDTX Comparison
Compare GGZ & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GGZ | BDTX |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.8M | 140.7M |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GGZ | BDTX |
|---|---|---|
| Price | $16.17 | $2.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $10.40 |
| AVG Volume (30 Days) | 6.3K | ★ 589.1K |
| Earning Date | 01-01-0001 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.45 |
| EPS | N/A | ★ 0.65 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.54 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.50 | $1.20 |
| 52 Week High | $16.80 | $4.94 |
Technical Indicators
Market Signals| Indicator | GGZ | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.57 | 50.52 |
| Support Level | $15.47 | $2.42 |
| Resistance Level | $16.35 | $2.67 |
| Average True Range (ATR) | 0.29 | 0.11 |
| MACD | -0.07 | 0.02 |
| Stochastic Oscillator | 29.35 | 61.76 |
Price Performance
Historical ComparisonAbout GGZ Gabelli Global Small and Mid Cap Value Trust (The) of Beneficial Interest
The Gabelli Global Small and Mid Cap Value Trust is a diversified closed-ended management investment company whose investment objective is long-term capital growth. It invests in equity securities such as common stock and preferred stock of companies.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.